XOMA

64 articles with XOMA

• XOMA to Present at H.C. Wainwright Global Investment Conference

  5/17/2022

  XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 10:00 AM ET.

• XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events

  5/5/2022

  XOMA Corporation reported its first quarter 2022 financial results and provided a recent operations update.

• XOMA Declares Quarterly Preferred Stock Dividends - Mar 21, 2022

  3/21/2022

  XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• XOMA to Present at Oppenheimer’s 32nd Annual Healthcare Conference

  3/10/2022

  XOMA Corporation announced today its Chairman and Chief Executive Officer, Jim Neal, will present at Oppenheimer’s 32nd Annual Healthcare Conference (virtual) on Thursday, March 17, 2022, at 12:40 PM ET.

• XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events

  3/8/2022

  XOMA Corporation, a biotech royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, reported its 2021 financial results and provided a recent operations update.

• XOMA to Present at the 42nd Annual Cowen Health Care Conference

  3/1/2022

  XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will be featured in a fireside chat at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022, at 1:30 PM ET.

• XOMA to Present at Aegis Capital Corp Investor Conference

  2/17/2022

  XOMA Corporation announced today its Chief Executive Officer, Jim Neal, will present at the Aegis Capital Corp Virtual Conference on February 24, 2022 at 11:00 AM ET. 

• 

  Predicting the Life Sciences Investment Market in 2022

  1/6/2022

  Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022. 

• XOMA Declares Quarterly Preferred Stock Dividends - Dec 23, 2021

  12/23/2021

  XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• XOMA to Present at Upcoming Investor Conferences - Dec 21, 2021

  12/21/2021

  XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences:

• XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events

  11/4/2021

  XOMA Corporation reported its third quarter 2021 financial results and provided a recent operations update.

• XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer

  11/4/2021

  XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3 development stage, triggering a $35 million milestone payment from Novartis. 

• XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

  9/22/2021

  XOMA Corporation (NASDAQ: XOMA)’s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021, at 10:20 AM PT.

• XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  9/13/2021

  XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference held on September 13-15, 2021. 

• XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events

  8/5/2021

  XOMA Corporation reported its second quarter 2021 financial results and provided a recent operations update.

• XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences

  7/15/2021

  XOMA Corporation, announced it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals’ vidutolimod, an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle, for $7.0 million upfront plus sales milestones.

• XOMA Declares Quarterly Preferred Stock Dividends

  6/21/2021

  XOMA Corporation today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock:

• XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting

  5/21/2021

  XOMA Corporation (Nasdaq: XOMA) recently learned its licensees are presenting at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 4-8, 2021, in a virtual setting.

• XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program

  5/3/2021

  XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen), as a result of the first patient dosed in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets.

• XOMA’s Royalty Portfolio Grows with Addition of Three Royalty Assets

  4/15/2021

  XOMA Corporation announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. innate cell engager programs for which XOMA could receive future economics.